Zobrazeno 1 - 10
of 90
pro vyhledávání: '"Martin Trbušek"'
Autor:
Stanislav Drápela, Miroslav Boudny, Josef Jaroš, Michaela Špunarová, Jan Verner, Prashant Khirsariya, Zuzana Jašková, Kamil Paruch, Yvona Brychtová, Marie Kasparkova, Jana Zemanová, Jiri Mayer, Marek Borsky, Václav Šeda, Jana Černá, Martin Trbušek, Alexandra Oltová, Marek Mráz, Karel Souček
Publikováno v:
Haematologica
Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::145501475952e3a04a814fab3a8f9fb2
https://doi.org/10.3324/haematol.2018.203430
https://doi.org/10.3324/haematol.2018.203430
Autor:
Viera Hrabčáková, Marek Borsky, Anna Panovská, Jitka Novotná, Michael Doubek, Petr Muller, Marek Mráz, Jiri Mayer, Martin Trbušek, Yvona Brychtová
Publikováno v:
Leukemia research. 111
The in vivo rituximab effects in B cell malignancies are only partially understood. Here we analyzed in a large chronic lymphocytic leukemia (CLL) cohort (n = 80) the inter-patient variability in CLL cell count reduction within the first 24 h of ritu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74469ca7bcd59b3b14845cbf96823a5a
https://pubmed.ncbi.nlm.nih.gov/34438120
https://pubmed.ncbi.nlm.nih.gov/34438120
Autor:
Miroslav Boudny, Martin Trbušek
Publikováno v:
Klinicka Onkologie. 33
Background: Signal transducer and activator of transcription (STAT) proteins are cytoplasmic tran-scription factors that transmit the signal of cytokines, hormones and growth factors. STAT pro-teins control fundamental cellular processes including su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a89717196f2a89a0b4345b9169586b5c
https://doi.org/10.14735/amko202032
https://doi.org/10.14735/amko202032
Autor:
Marie Jarošová, Heidi Mocikova, Jan Oppelt, Leos Kren, Vít Procházka, Katerina Machova Polakova, Pavel Burda, Olaf Merkel, Katerina Cerna, Robert Pytlik, Ana-Iris Schiefer, Marek Trneny, Lenka Zlamalikova, Martin Trbušek, Ján Deván, Lenka Kruzova, Ingrid Simonitsch-Klupp, Václav Šeda, Sonali Sharma, Zuzana Prouzová, Andrea Janíková, Katerina Musilova, Andrew G. Evans, Gabriela Pavlasova, Clive S. Zent, Jiri Mayer, Kvetoslava Liskova, Andrea Marečková, Christoph Kornauth, Marek Mráz
Publikováno v:
Blood. 132:2389-2400
Follicular lymphoma (FL) is a common indolent B-cell malignancy with a variable clinical course. An unfavorable event in its course is histological transformation to a high-grade lymphoma, typically diffuse large B-cell lymphoma. Recent studies show
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e57cf8c8ebb70ea36bff26c8c2b49d6a
https://doi.org/10.1182/blood-2018-06-855502
https://doi.org/10.1182/blood-2018-06-855502
Autor:
Martin Trbušek, Miroslav Boudny
Publikováno v:
Cancer treatment reviews. 88
Progress in cancer therapy changed the outcome of many patients and moved therapy from chemotherapy agents to targeted drugs. Targeted drugs already changed the clinical practice in treatment of leukemias, such as imatinib (BCR/ABL inhibitor) in chro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f5b35a3b24233d1ea1684043029aca8
https://pubmed.ncbi.nlm.nih.gov/32592909
https://pubmed.ncbi.nlm.nih.gov/32592909
Autor:
Anna Brzobohata, Hana Skuhrová Francová, Jiri Mayer, Michael Doubek, Anna Panovská, Šárka Pavlová, Michaela Špunarová, Marek Mráz, Nikola Tom, Šárka Pospíšilová, Martin Trbušek, Yvona Brychtová
Publikováno v:
Leukemia research. 81
The impact of genetic aberrations on rituximab-based therapeutic regimens has been intensely studied in chronic lymphocytic leukemia (CLL). According to the current consensus chemoimmunotherapy consisting of rituximab and DNA-damaging drugs is not su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c714c0c2ef127a5a3963ea5031b05874
https://pubmed.ncbi.nlm.nih.gov/31054420
https://pubmed.ncbi.nlm.nih.gov/31054420
Autor:
Mojmír Moulis, Jitka Malčíková, Jiri Mayer, Jana Šmardová, Martin Trbušek, Andrea Marečková, David Šálek, Karol Pál, Lenka Radová, Andrea Janíková, Nikola Tom, Leos Kren
Publikováno v:
Leukemialymphoma. 60(6)
Mantle cell lymphoma (MCL) is characterized by the hallmark t(11;14)(q13;q32) translocation, leading to cyclin D1 over-expression. Additionally, disrupting the DNA damage response pathway through ATM or TP53 defects plays an important role in MCL pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e84c2ce74dd4b5b9db7d784b5c32c92
https://pubmed.ncbi.nlm.nih.gov/30626249
https://pubmed.ncbi.nlm.nih.gov/30626249
Autor:
Matthew S. Davids, Jiri Mayer, Gabriela Pavlasova, Jennifer R. Brown, Martin Trbušek, Marek Mráz, Michael Doubek, Marek Borsky, Thomas J. Kipps, Šárka Pospíšilová, Katerina Cerna, Raffaele A. Calogero, Jitka Osičková, Václav Šeda
Publikováno v:
Blood. 128:1609-1613
Agents targeting B-cell receptor (BCR) signaling-associated kinases such as Bruton tyrosine kinase (BTK) or phosphatidylinositol 3-kinase can induce mobilization of neoplastic B cells from the lymphoid tissues into the blood, which makes them potenti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::423db15c342025b2a064225aff5733f6
https://doi.org/10.1182/blood-2016-04-709519
https://doi.org/10.1182/blood-2016-04-709519
Autor:
Yvona Brychtová, Alexandra Oltová, Pavel Vesely, Jan Verner, Martin Trbušek, Kristina Zaprazna, Pavlína Janovská, Jiri Kohoutek, Zuzana Jašková, Marek Borsky, Ondrej Hylse, Vitezslav Bryja, Kamil Paruch, Marta Dzimkova, Marie Kasparkova, Jana Zemanová, Jana Collakova
Publikováno v:
Oncotarget
Oncotarget. 2016, vol. 7, issue 38, p. 1-16.
Oncotarget. 2016, vol. 7, issue 38, p. 1-16.
// Jana Zemanova 1 , Ondrej Hylse 2, 3 , Jana Collakova 4, 5 , Pavel Vesely 5 , Alexandra Oltova 1 , Marek Borsky 1 , Kristina Zaprazna 6 , Marie Kasparkova 1 , Pavlina Janovska 7 , Jan Verner 1 , Jiri Kohoutek 8 , Marta Dzimkova 8 , Vitezslav Bryja
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a2b3d1b5a113cc55297636e259ae30c
https://doi.org/10.18632/oncotarget.11388
https://doi.org/10.18632/oncotarget.11388
Publikováno v:
Leukemia Research. 89:106288
TP53 gene defects represent the most unfavorable prognostic factor in chronic lymphocytic leukemia (CLL). Although recently introduced small-molecule B-cell receptor signalling inhibitors have revolutionized CLL treatment, data for ibrutinib still po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b1fbae67b51643ec81fbb76e4980c75
https://doi.org/10.1016/j.leukres.2019.106288
https://doi.org/10.1016/j.leukres.2019.106288